Q32 Bio Inc (QTTB) Stock Price, Quote & News

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic derm...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 999 0232

Website: www.q32bio.com

Address:

830 Winter Street, Waltham, United States

d_risk Nov. 13 at 1:44 PM

$QTTB - Q32 Bio Inc. Common Stock - 10Q - Updated Risk Factors QTTB’s latest 10-Q risk factors spotlight heightened competition in drug development, expanded uncertainties around bempikibart’s approval and commercialization, new regulatory and IP hurdles, evolving global compliance and pricing pressures, workforce reductions, and Nasdaq listing risks—while trimming prior concerns on product liability, litigation, and Sarbanes-Oxley compliance. #Biotechnology #NasdaqListing #PricingPressure #RegulatoryRisk #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/QTTB/10-Q/2025-11-13

0 · Reply

Dont1follow2me3 Nov. 12 at 2:39 PM

$QTTB

0 · Reply

NotHopeJustFacts Nov. 8 at 5:25 PM

$ABAT $BYND $QTTB $TMQ imagine this clown @Cwiden1 who is a BYND bag holder cheerleader trying to ignore my record while is 50% down from my post and I keep enjoying my PUTS options, some people would never learn cause once a loser always a loser

1 · Reply

Dont1follow2me3 Nov. 6 at 11:49 PM

$QTTB

0 · Reply

Nate_HTX Nov. 6 at 5:22 PM

$QTTB buying here at 2.37 at trendline

0 · Reply

Stef_DL Nov. 5 at 2:36 PM

$QTTB It's still waiting for real news. The last month proved that a recovery is very possible. Gap fill still pending.

0 · Reply

Bluesclues692 Nov. 5 at 12:27 AM

$QTTB going through a super low volume stage now yeah

0 · Reply

HockeyBob Nov. 4 at 8:09 PM

$QTTB It appears people gave up on this stock or at least talking about...has potential :)

0 · Reply

Dont1follow2me3 Nov. 3 at 2:38 AM

$QTTB

0 · Reply

BostonWICKEDTrader Oct. 30 at 11:12 PM

$QTTB great price...chart looks rip for a big move..

0 · Reply

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 6:59 AM EDT - 25 days ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Aug 28, 2025, 6:59 AM EDT - 2 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 6, 2025, 6:59 AM EDT - 3 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 25, 2025, 6:59 AM EDT - 5 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

May 8, 2025, 6:59 AM EDT - 6 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 30, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Mar 11, 2025, 6:59 AM EDT - 8 months ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 8, 2025, 11:00 AM EST - 9 months ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Feb 28, 2025, 9:00 AM EST - 9 months ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 26, 2025, 6:59 AM EST - 9 months ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 10, 2025, 4:05 PM EST - 9 months ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 4, 2025, 4:05 PM EST - 10 months ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 3:40 AM EDT - 1 year ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

AIU COMM EBS HE HUMA SAVA SERV

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

May 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Mar 25, 2024, 4:15 PM EDT - 1 year ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

d_risk Nov. 13 at 1:44 PM

0 · Reply

Dont1follow2me3 Nov. 12 at 2:39 PM

$QTTB

0 · Reply

NotHopeJustFacts Nov. 8 at 5:25 PM

1 · Reply

Dont1follow2me3 Nov. 6 at 11:49 PM

$QTTB

0 · Reply

Nate_HTX Nov. 6 at 5:22 PM

$QTTB buying here at 2.37 at trendline

0 · Reply

Stef_DL Nov. 5 at 2:36 PM

$QTTB It's still waiting for real news. The last month proved that a recovery is very possible. Gap fill still pending.

0 · Reply

Bluesclues692 Nov. 5 at 12:27 AM

$QTTB going through a super low volume stage now yeah

0 · Reply

HockeyBob Nov. 4 at 8:09 PM

$QTTB It appears people gave up on this stock or at least talking about...has potential :)

0 · Reply

Dont1follow2me3 Nov. 3 at 2:38 AM

$QTTB

0 · Reply

BostonWICKEDTrader Oct. 30 at 11:12 PM

$QTTB great price...chart looks rip for a big move..

0 · Reply

massivelife Oct. 30 at 8:39 PM

$QTTB

0 · Reply

massivelife Oct. 30 at 2:15 PM

$QTTB price

0 · Reply

Mayneverretire Oct. 29 at 4:28 PM

$QTTB

0 · Reply

amaaaa Oct. 28 at 1:20 PM

$QTTB let’s go

0 · Reply

silentmaxx Oct. 27 at 2:47 PM

$QTTB

1 · Reply

Joemodz Oct. 27 at 2:01 PM

$QTTB when do we expect the next catalyst here?

0 · Reply

Mayneverretire Oct. 24 at 10:34 PM

$QTTB

0 · Reply

Mayneverretire Oct. 24 at 4:57 PM

$QTTB

0 · Reply

Mayneverretire Oct. 24 at 3:38 PM

$QTTB

0 · Reply

Mayneverretire Oct. 24 at 2:04 PM

$QTTB

0 · Reply

RetireQuick Oct. 23 at 5:40 PM

$QTTB bought the dip here and loaded up. Like the risk / reward.

0 · Reply

NotHopeJustFacts Oct. 23 at 1:32 PM

$BYND $ABAT $QTTB $TMQ I do not buy POS stocks, I look at Put options when I see clowns pumping POS stocks but you already knew that, go cry foul play for your lack of education

2 · Reply

Market Cap	26.96M
Revenue (ttm)	0.00
Net Income (ttm)	-47.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.04

Volume	35,700
Avg Vol	264,398
Day's Range	N/A - N/A
Shares Out	12.20M
Stochastic %K	8%
Beta	0.15
Analysts	Sell
Price Target	$12.00